Major boost for combatting drug addiction in Scotland as SMC gives green light to new wafer-thin treatment
Espranor represents the first major advance available in opioid substitution therapy for 10 years.
Martindale Pharma has announced that the Scottish Medicines Consortium (SMC) has recommended Espranor (buprenorphine oral lyophilisate), a new treatment for opioid drug addiction, for restricted use within NHS Scotland. This first fast-dissolving treatment has been approved as a substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment for patients aged 15 years and over who have agreed to be treated for opioid drug addiction and for whom methadone is not suitable. Espranor represents the first major advance available in opioid substitution therapy (OST) for 10 years.
“For many of us the current drug problem needs new solutions, one of which is a bigger range of opiates and modalities of delivery than is currently available for medical assisted treatment. Espranor is a significant advance in extending the management of opiate drug problems in its ability to dramatically reduce supervision time allowing, or eliminating, some of the limiting factors in daily management in communities and custody situations,” said Roy Robertson, a GP in Edinburgh, Professor of Addiction Medicine at Edinburgh University and Chair of the Scottish Government group on Harm Reduction. “Espranor has the potential to extend treatment to a large group and to draw in those currently not in supportive treatment. This could be a serious advantage in our attempts to limit the damage and prevent the alarming rate of drug related deaths.” The majority of people in Scotland accessing opioid substitution therapy are treated with methadone and just over 15% receive buprenorphine or buprenorphine and naloxone. Licenced buprenorphine is currently in the form of a compressed sublingual tablet which usually takes between 5 and 10 minutes to dissolve and carries the risk of diversion and misuse. As a result of this patients may experience close supervision throughout their treatment and this lengthy supervised self-administration procedures are often regarded as humiliating and such stigma presents a barrier to buprenorphine uptake. Current treatments still fail many patients, with approximately 50% of patients dropping out of both buprenorphine and methadone maintenance treatment within 6 months.
“Combating opioid addiction is a huge issue in Scotland and today’s announcement is great news for patients who want to be treated for their addiction but are failing on their current treatment,” said Annemarie Ward, CEO of Faces and Voices of Recovery. “Having another choice of treatment available is always a cause for celebration and now being able to offer a simpler form of buprenorphine, we may increase its use and reduce some of the problems seen with conventional pills.”
Recently published data on Espranor show that, when compared with current hard sublingual (under the tongue) tablets, the novel formulation dissolved quickly with no increased respiratory safety risk or concerns and no significant difference in efficacy.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance